Comparative Pharmacology
Head-to-head clinical analysis: SUDAFED 12 HOUR versus TRINALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUDAFED 12 HOUR versus TRINALIN.
SUDAFED 12 HOUR vs TRINALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
TRINALIN is a combination of azatadine, a first-generation antihistamine that antagonizes histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
One tablet (azatadine 1 mg/pseudoephedrine 120 mg) orally every 12 hours. Not to exceed 2 tablets in 24 hours.
None Documented
None Documented
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (CrCl <30 mL/min); shorter in children (3-4 hours)
Terminal elimination half-life approximately 20-30 hours; clinical context: allows twice-daily dosing for sustained decongestant effect
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30%
Category C
Category C
Decongestant
Antihistamine/Decongestant